Tags

Type your tag names separated by a space and hit enter

Up Is Down - Pharmaceutical Industry Caution vs. Federal Acceleration of Covid-19 Vaccine Approval.
N Engl J Med. 2020 Oct 29; 383(18):1706-1708.NEJM

Authors+Show Affiliations

From the Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School - both in Boston.From the Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School - both in Boston.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32931162

Citation

Avorn, Jerry, and Aaron S. Kesselheim. "Up Is Down - Pharmaceutical Industry Caution Vs. Federal Acceleration of Covid-19 Vaccine Approval." The New England Journal of Medicine, vol. 383, no. 18, 2020, pp. 1706-1708.
Avorn J, Kesselheim AS. Up Is Down - Pharmaceutical Industry Caution vs. Federal Acceleration of Covid-19 Vaccine Approval. N Engl J Med. 2020;383(18):1706-1708.
Avorn, J., & Kesselheim, A. S. (2020). Up Is Down - Pharmaceutical Industry Caution vs. Federal Acceleration of Covid-19 Vaccine Approval. The New England Journal of Medicine, 383(18), 1706-1708. https://doi.org/10.1056/NEJMp2029479
Avorn J, Kesselheim AS. Up Is Down - Pharmaceutical Industry Caution Vs. Federal Acceleration of Covid-19 Vaccine Approval. N Engl J Med. 2020 Oct 29;383(18):1706-1708. PubMed PMID: 32931162.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Up Is Down - Pharmaceutical Industry Caution vs. Federal Acceleration of Covid-19 Vaccine Approval. AU - Avorn,Jerry, AU - Kesselheim,Aaron S, Y1 - 2020/09/15/ PY - 2020/9/16/pubmed PY - 2020/11/6/medline PY - 2020/9/15/entrez SP - 1706 EP - 1708 JF - The New England journal of medicine JO - N Engl J Med VL - 383 IS - 18 SN - 1533-4406 UR - https://www.unboundmedicine.com/medline/citation/32931162/Up_Is_Down___Pharmaceutical_Industry_Caution_vs__Federal_Acceleration_of_Covid_19_Vaccine_Approval_ L2 - https://www.nejm.org/doi/10.1056/NEJMp2029479?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -